CURE13h
FDA Grants Breakthrough Therapy to IDE196 in Primary Uveal Melanoma
The FDA granted Breakthrough Therapy designation to IDE196 for the neoadjuvant treatment of primary uveal melanoma when ...
Fierce Pharma14h
Amgen wins key rare disease nod for Uplizna, checking off one goal in expansion push
With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...
Renal & Urology News15h
Prostate Cancer Imaging Agent Gozellix Gets FDA Approval
The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection), a radioactive diagnostic agent for prostate cancer detection.
Renal & Urology News15h
Fabhalta Approved as First Treatment for C3 Glomerulopathy
The FDA has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.
Amgen gets expanded FDA label approval for Uplizna
Amgen (NASDAQ: NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label approval ...
Verywell Health1d
10 Supplements for Stronger Lungs and Easier Breathing
Learn more about supplements for lung health, including vitamins, minerals, and herbs that support breathing, reduce ...
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...
Arkansas law allows ivermectin sale sans prescription, defying FDA; pharmacists wary
Governor Sanders signed Act 396 into law, allowing Arkansans to purchase ivermectin without a prescription for human use—but ...
MedPage Today1d
IgA Nephropathy Drug With Novel Mechanism Wins FDA Approval
The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...